S1P Receptor Mechanisms in Neuropathic Pain
神经性疼痛中的 S1P 受体机制
基本信息
- 批准号:9750825
- 负责人:
- 金额:$ 54.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-15 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:Absence of pain sensationAcuteAgonistAnalgesicsAstrocytesAttenuatedBehaviorCellsChronicDataDepressed moodDevelopmentDiseaseDoseDown-RegulationEffectivenessEnterobacteria phage P1 Cre recombinaseFDA approvedG-Protein-Coupled ReceptorsGTP-Binding ProteinsGene TargetingGeneticImmuneInflammationInflammatoryLigandsLumbar spinal cord structureMediatingMediator of activation proteinMicrogliaModelingMultiple SclerosisMusNerveNervous system structureNeuraxisNeurogliaNeuronsNeuropathyNociceptionNociceptorsOralOutcome StudyPainPatientsPeripheralPharmaceutical PreparationsPharmacologyPharmacotherapyPlayProdrugsPublishingQuality of lifeRegulationRelapseResistanceRodentRoleSiteSphingolipidsSphingosine-1-Phosphate ReceptorSpinalSpinal CordSystemTestingThermal HyperalgesiasTimebasecell typechronic constriction injurychronic paindesensitizationedg-1 Proteinexperimental studygenetic approachgenetic manipulationglial activationinorganic phosphatemechanical allodyniamidbrain central gray substancemotor impairmentmouse modelnerve injurynestin proteinneuroregulationnovelnovel therapeuticspain modelpainful neuropathypromoterprotein activationpublic health relevancereceptorreceptor functionresponsesciatic nervesham surgeryside effectsphingosine 1-phosphatetargeted treatmenttherapeutic targettrafficking
项目摘要
DESCRIPTION (provided by applicant): Chronic pain diminishes the quality of life for millions of patients, but currently used classes of analgesics possess varied efficacy and are associated with a variety of untoward side effects. Thus, novel targets to treat chronic pain and development of new drugs that have better efficacy and/or fewer side effects than existing pharmacotherapies are greatly needed. A particularly promising target is the sphingosine-1-phosphate (S1P) receptor system, which mediates CNS neuromodulatory functions. FTY720-phosphate, the active metabolite of FTY720 (FTY; fingolimod), approved by the FDA for treatment of relapsing multiple sclerosis, acts as an agonist at four of the five S1P receptors (S1P1, 3, 4, 5). Interestingly, studies have demonstrated that FTY and other S1P receptor (S1PR) agonists produce antinociception in acute thermal rodent pain models and these effects are blocked by central administration of an S1P1-selective antagonist. Moreover, FTY reverses hyperalgesic states in rodent neuropathic pain models. However, it is unclear whether S1P1 or other S1PR subtypes mediate these effects and their site(s) of action. Thus, the overarching hypothesis of this application is that the S1P1 receptor represents a novel and promising target for the treatment of neuropathic pain. Here, we will test whether S1P1 receptors in the CNS mediate anti-hyperalgesic effects in a mouse neuropathic pain model, using a combination of pharmacological and gene targeting approaches. Therefore, the Specific Aims are to: 1) Determine the role of S1P1Rs in alleviation of neuropathic pain by S1PR ligands; 2) Determine the role of FTY-induced S1PR adaptation in FTY-mediated reversal of neuropathic pain; and 3) Determine the role of S1P and S1P1 receptors in spinal glia in CCI-induced neuropathic pain and its reversal by FTY. The studies proposed herein will establish whether FTY and selective S1PR ligands reverse pain-related behavior in the mouse CCI neuropathic pain model, whether S1P1 receptors in the nervous system mediate these actions and the specific cell types involved in the response. In order to be useful in treating chronic pain, the drug must retain its effectiveness during prolonged treatment. Thus, evidence supporting a role of S1P1 in specific cell types to reduce neuropathic pain without tolerance or motor impairment will provide proof of principle that S1P1 receptors are a viable target to treat neuropathic pain and possibly other chronic pain-related disorders.
描述(申请人提供):慢性疼痛降低了数百万患者的生活质量,但目前使用的各类止痛药具有不同的疗效,并与各种不良副作用有关。因此,迫切需要治疗慢性疼痛的新靶点和开发比现有药物疗法更有效和/或副作用更少的新药。一个特别有希望的靶点是鞘氨醇-1-磷酸(S1P)受体系统,它介导中枢神经调节功能。FTY720-磷酸是FTY720(FTY;Fingolimod)的活性代谢物,FDA批准用于治疗复发性多发性硬化症,它是五个S1P受体中的四个(S1P1、3、4、5)的激动剂。有趣的是,研究表明FTY和其他S1P受体(S1PR)激动剂在急性热性啮齿动物疼痛模型中产生抗伤害作用,这些作用可被中枢注射S1P1选择性拮抗剂阻断。此外,FTY逆转了啮齿动物神经病理性疼痛模型中的痛觉过敏状态。然而,目前尚不清楚S1P1或其他S1PR亚型是否介导了这些影响及其作用部位(S)。因此,这一应用的主要假设是S1P1受体代表了治疗神经病理性疼痛的一个新的和有希望的靶点。在这里,我们将使用药理学和基因靶向相结合的方法,在小鼠神经病理性疼痛模型中测试中枢神经系统中的S1P1受体是否介导了抗痛觉过敏效应。因此,本研究的具体目的是:1)确定S1P1Rs在S1PR配体减轻神经病理性疼痛中的作用;2)确定FTY诱导的S1PR适应在FTY介导的神经病理性疼痛逆转中的作用;3)确定脊髓胶质细胞S1P和S1P1受体在CCI诱导的神经病理性疼痛中的作用及其FTY的逆转作用。本文提出的研究将确定FTY和选择性S1PR配体是否逆转了小鼠CCI神经病理性疼痛模型中的疼痛相关行为,神经系统中的S1P1受体是否介导了这些行为,以及参与反应的特定细胞类型。为了有效地治疗慢性疼痛,这种药物必须在长期治疗过程中保持其有效性。因此,支持S1P1在特定细胞类型中发挥作用的证据将提供证据,证明S1P1受体是治疗神经性疼痛和其他可能的慢性疼痛相关疾病的可行靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kurt F Hauser其他文献
Kurt F Hauser的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kurt F Hauser', 18)}}的其他基金
Chloride channel-dependent mechanisms of opiate and HIV-induced synaptodendritic injury
阿片类药物和 HIV 诱导的突触树突损伤的氯离子通道依赖性机制
- 批准号:
10704734 - 财政年份:2022
- 资助金额:
$ 54.16万 - 项目类别:
Chloride channel-dependent mechanisms of opiate and HIV-induced synaptodendritic injury
阿片类药物和 HIV 诱导的突触树突损伤的氯离子通道依赖性机制
- 批准号:
10548312 - 财政年份:2022
- 资助金额:
$ 54.16万 - 项目类别:
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity
解决阿片类药物-神经艾滋病毒合并症中的兴奋性中枢神经系统/神经元损伤的创新治疗方法
- 批准号:
10573827 - 财政年份:2022
- 资助金额:
$ 54.16万 - 项目类别:
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity
解决阿片类药物-神经艾滋病毒合并症中的兴奋性中枢神经系统/神经元损伤的创新治疗方法
- 批准号:
10684110 - 财政年份:2022
- 资助金额:
$ 54.16万 - 项目类别:
Selective vulnerability of discrete neural circuits in the striatum to HIV-opiate comorbidity
纹状体中离散神经回路对艾滋病毒-阿片类共病的选择性脆弱性
- 批准号:
10317037 - 财政年份:2018
- 资助金额:
$ 54.16万 - 项目类别:
HIV opiate interactions in white matter pathology
HIV阿片类药物在白质病理学中的相互作用
- 批准号:
9419501 - 财政年份:2017
- 资助金额:
$ 54.16万 - 项目类别:
HIV opiate interactions in white matter pathology
HIV阿片类药物在白质病理学中的相互作用
- 批准号:
10189540 - 财政年份:2017
- 资助金额:
$ 54.16万 - 项目类别:
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection
二价配体作为化学探针研究阿片类药物滥用增强的 HIV 感染
- 批准号:
9924466 - 财政年份:2017
- 资助金额:
$ 54.16万 - 项目类别:
相似海外基金
Elucidation of acute poisoning mechanism due to abuse of CB1 receptor agonist.
阐明滥用 CB1 受体激动剂引起的急性中毒机制。
- 批准号:
21K17323 - 财政年份:2021
- 资助金额:
$ 54.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of acute poisoning mechanism due to abuse of CB1 receptor agonist.
阐明滥用 CB1 受体激动剂引起的急性中毒机制。
- 批准号:
19K19485 - 财政年份:2019
- 资助金额:
$ 54.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Tissue repair effect in acute myocardial infarction through mobilization of endogenous Muse cells by sphingosine-1-phosphate receptor 2 agonist
1-磷酸鞘氨醇受体2激动剂动员内源性Muse细胞对急性心肌梗死的组织修复作用
- 批准号:
18K15843 - 财政年份:2018
- 资助金额:
$ 54.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
- 批准号:
6115624 - 财政年份:1998
- 资助金额:
$ 54.16万 - 项目类别:
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
- 批准号:
6219539 - 财政年份:1998
- 资助金额:
$ 54.16万 - 项目类别:
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
- 批准号:
6276858 - 财政年份:1997
- 资助金额:
$ 54.16万 - 项目类别:
ACUTE CHRONIC HORMONAL CHANGES WITH LHRH-AGONIST THERAPY
LHRH 激动剂治疗引起的急性慢性荷尔蒙变化
- 批准号:
6250152 - 财政年份:1997
- 资助金额:
$ 54.16万 - 项目类别:
ACUTE CHRONIC HORMONAL CHANGES WITH LHRH-AGONIST THERAPY
LHRH 激动剂治疗引起的急性慢性荷尔蒙变化
- 批准号:
6279945 - 财政年份:1997
- 资助金额:
$ 54.16万 - 项目类别:
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
- 批准号:
6246787 - 财政年份:1997
- 资助金额:
$ 54.16万 - 项目类别:
PSYCHOPHARMACOLOGY OF DA AGONIST CNS EFFECTS: ACUTE AND CHRONIC STUDIES
DA 激动剂中枢神经系统影响的精神药理学:急性和慢性研究
- 批准号:
3891471 - 财政年份:
- 资助金额:
$ 54.16万 - 项目类别: